Lag3 - lymphocyte activating 3 Gene

Also Known as CD223

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 297596

Summary

Predicted to enable MHC class II protein binding activity and transmembrane signaling receptor activity. Predicted to be involved in several processes, including cell surface receptor signaling pathway; negative regulation of regulatory T cell differentiation; and plasmacytoid dendritic cell activation. Predicted to act upstream of or within negative regulation of T cell activation; negative regulation of interleukin-2 production; and positive regulation of natural killer cell mediated cytotoxicity. Predicted to be located in external side of plasma membrane and extracellular region. Orthologous to human LAG3 (lymphocyte activating 3). [provided by Alliance of Genome Resources, Apr 2022]

Lag3 Products (1)

mRNA Protein Name
NM_212513.2 NP_997678.2 lymphocyte activation gene 3 protein precursor
Protein Preferred Names Protein Names

lymphocyte activation gene 3 protein

  • LAG-3

  • lymphocyte-activation gene 3

Recombinant Lag3 Proteins

Cat. No. Product Name Accession Purity
HY-P74788 LAG-3 Protein, Rat (HEK293, His) Q5BK54 (G24-L442) ≥ 90%, as determined by reducing SDS-PAGE.

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive MoleculesInhibitory Antibodies (15)
Cat. No. Product Name Effect
Purity Phase
HY-P99156 Relatlimab 98.00% Phase 4
HY-P99573 Tebotelimab 99.52% Phase 3
HY-P99613 Favezelimab 97.79% Phase 3
HY-P99617 Fianlimab 99.04% Phase 3
HY-P990968 Alcestobart 98.383% Phase 3
HY-P99027 Ieramilimab ≥99.0% Phase 2
HY-P990750 Negalstobart 96.89% Phase 2
HY-P990700 Tobemstomig 97.06% Phase 2
HY-P99736 Miptenalimab 97.04% Phase 2
HY-P990046 Tuparstobart 97.65% Phase 2
HY-P990740 Fanastomig 95.478% Phase 2
HY-P991300 GSK2831781 Inhibitor / Phase 2
HY-P991605 HLX26 Inhibitor / Phase 2
HY-P991301 IMP-761 Inhibitor 97.24% Phase 1
HY-P991303 TQB-2223 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (21)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-108691 PF-06465469 Inhibitor 99.48% Unkown
HY-144088 ZYF0033 Inhibitor 98.82% Unkown
HY-172930 PVTX-405 / Unkown
HY-176813 LAG-3 Hit II Inhibitor 99.58% Unkown
HY-162811 LAG-3 biner 1 97.08% Unkown
HY-164308 SA-15-P Inhibitor 99.62% Unkown
HY-122081 CPI-644 Inhibitor / Unkown
HY-145240 eIF4E-IN-1 Inhibitor / Unkown
HY-149916 A2AR-antagonist-1 Antagonist 96.68% Unkown
HY-176814 LAG-3-IN-1 Inhibitor / Unkown
HY-178320 LAG-3-IN-2 Inhibitor / Unkown
HY-179060 LAG-3 PROTAC-1 Degrader / Unkown
HY-179061 LAG-3 degrader 1 Degrader / Unkown
HY-179071 DAPK1 ligand-1 Degrader / Unkown
HY-180900 Z3071585108 Ligand / Unkown
HY-181685 LAGi-DEL Inhibitor / Unkown
HY-P10835 LAG-3 cyclic peptide inhibitor C25 Inhibitor / Unkown
HY-P10837 LAG-3 cyclic peptide inhibitor 12 Inhibitor / Unkown
HY-RS07492 LAG3 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS16686 Lag3 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23121 Lag3 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Bioactive MoleculesInhibitory Antibodies (15)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P99141 Anti-Mouse LAG-3 Antibody (C9B7W) Inhibitor 99% Unkown
HY-P99922 Encelimab Inhibitor 95.25% Unkown
HY-P990976 Brivestobart 99.198% Unkown
HY-P990912 Cugrastomig 98.46% Unkown
HY-P99354 Bavunalimab 99.408% Unkown
HY-P991297 AM0003 Inhibitor / Unkown
HY-P991298 DNV-3 Inhibitor / Unkown
HY-P991299 ENUM006 Inhibitor / Unkown
HY-P991302 KL-A289 Inhibitor / Unkown
HY-P992075 Anti-Bovine LAG-3 Antibody (2D8) Inhibitor / Unkown
HY-P992254 Anti-LAG-3 Antibody (BAP050) Inhibitor / Unkown
HY-P992352 ES005 / Unkown
HY-P992461 SHR-1802 Inhibitor / Unkown
HY-P990204 Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) Inhibitor / Unkown
HY-P992156 Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Lag3 NCBI NCBI:3902
Macaca fascicularis Lag3 NCBI NCBI:102122272
Mus musculus Lag3 NCBI NCBI:16768